Linking inflammation and cardiovascular disease: the emerging role of lipoprotein-associated phosphoplipase A2
Journal
Ukrainian Journal of Cardiology
Date Issued
2025-12
Author(s)
Kostovska, Irena
Abstract
Over the past decades, inflammation has been recognized as a key contributor to the development of atherosclerosis, prompting extensive research. Numerous inflammatory markers have demonstrated predictive value for both initial and recurrent coronary events in individuals with or without established coronary vascular disease (CVD). Among these, lipo protein associated phospholipase A2 (Lp PLA2) has garnered significant attention. Lp PLA2 may be involved in the athero sclerotic process and contribute to plaque destabilization through its inflammatory activity within atherosclerotic lesions.
Lipoprotein associated phospholipase A2 (Lp PLA2), a recently identified cardiovascular specific inflammatory mediator, is closely associated with the onset and progression of cardiovascular events. This review explores the potential of Lp PLA2 as both a risk marker and a therapeutic target in CVD. Elevated levels of Lp PLA2 mass and activity have been linked to an increased risk of CVD in both the general population and patients with pre existing disease. However, it remains uncer tain whether incorporating Lp PLA2 measurements into risk prediction models significantly enhances risk stratification beyond traditional cardiovascular risk factors. Additionally, the failure of darapladib, a potent and selective Lp PLA2 inhibitor, to reduce CVD events in major randomized, placebo controlled trials suggests the importance of ongoing research to fully understand its functions and develop effective strategies for CVD prevention and treatment.
Lipoprotein associated phospholipase A2 (Lp PLA2), a recently identified cardiovascular specific inflammatory mediator, is closely associated with the onset and progression of cardiovascular events. This review explores the potential of Lp PLA2 as both a risk marker and a therapeutic target in CVD. Elevated levels of Lp PLA2 mass and activity have been linked to an increased risk of CVD in both the general population and patients with pre existing disease. However, it remains uncer tain whether incorporating Lp PLA2 measurements into risk prediction models significantly enhances risk stratification beyond traditional cardiovascular risk factors. Additionally, the failure of darapladib, a potent and selective Lp PLA2 inhibitor, to reduce CVD events in major randomized, placebo controlled trials suggests the importance of ongoing research to fully understand its functions and develop effective strategies for CVD prevention and treatment.
File(s)![Thumbnail Image]()
Loading...
Name
Ukrainian journal of cardiology.pdf
Size
369.18 KB
Format
Adobe PDF
Checksum
(MD5):f86ec7c2fba8853b887752013cd603a6